HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The premenstrual syndrome. Effects of "medical ovariectomy".

Abstract
In a crossover study conducted over a six-month period in eight patients with well-characterized premenstrual syndrome, physical and behavioral symptoms were relieved by daily administration of an agonist of gonadotropin-releasing hormone. The reversible "medical ovariectomy" attained with this agonist suggests that it may be an effective and rational treatment for this distressing syndrome in the short term. Whether prolonged therapy would be safe and effective, or even necessary, remains to be determined.
AuthorsK N Muse, N S Cetel, L A Futterman, S C Yen
JournalThe New England journal of medicine (N Engl J Med) Vol. 311 Issue 21 Pg. 1345-9 (Nov 22 1984) ISSN: 0028-4793 [Print] United States
PMID6387488 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Hormones
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • Tryptal
Topics
  • Adult
  • Clinical Trials as Topic
  • Female
  • Gonadotropin-Releasing Hormone (analogs & derivatives, pharmacology, therapeutic use)
  • Hormones (pharmacology, therapeutic use)
  • Humans
  • Menstruation (drug effects)
  • Premenstrual Syndrome (drug therapy)
  • Syndrome
  • Triptorelin Pamoate (analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: